Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoGen, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review
From ImmunoGen
Via Business Wire
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30... 
Via FinancialNewsMedia
Topics Death
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... 
Via FinancialNewsMedia
Topics Intellectual Property
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Reports Recent Progress and 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ImmunoGen, Inc.
Via Business Wire
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options... 
Via FinancialNewsMedia
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Proposed Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
From ImmunoGen Inc.
Via Business Wire
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
From ImmunoGen
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.